Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s share price traded down 9.1% on Monday . The stock traded as low as $10.66 and last traded at $10.49. 50,088 shares were traded during mid-day trading, a decline of 37% from the average session volume of 79,571 shares. The stock had previously closed at $11.54.
Gyre Therapeutics Stock Performance
The firm's 50-day simple moving average is $11.43 and its two-hundred day simple moving average is $12.33.
Insider Buying and Selling
In related news, President Songjiang Ma sold 2,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the sale, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 30,054 shares of company stock worth $342,277. 19.52% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock valued at $84,000 after buying an additional 1,996 shares during the last quarter. Northern Trust Corp lifted its stake in Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock valued at $1,251,000 after acquiring an additional 8,624 shares during the last quarter. Barclays PLC lifted its stake in Gyre Therapeutics by 13.5% in the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock valued at $128,000 after acquiring an additional 1,255 shares during the last quarter. Wells Fargo & Company MN grew its position in Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after acquiring an additional 913 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Gyre Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock worth $1,386,000 after purchasing an additional 918 shares during the last quarter. 23.99% of the stock is owned by institutional investors and hedge funds.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
See Also
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
